Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Montserrat Plana has a total of 200 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Challenges in the Vaccination of HIV-Infected Individuals

    by Marta Sisteré-Oró, Roberto Güerri-Fernandez, Montserrat Plana, Gennady Bocharov, Andreas Meyerhans

    Vaccination of people living with an HIV infection (PLWH) remains a worldwide challenge. The reason is the heterogeneity of this group that comprises people with and without highly active retroviral treatment and varying degrees of immunosuppression. In this review, we (i) highlight the impact of antiviral treatment success on vaccination outcomes, (ii) describe the current vaccine recommendations for PLWH, and (iii) summarize immunotherapeutic strategies for improved HIV immune control.

  • Open Access

    Immunogenicity and Safety of PHH-1V COVID-19 Vaccine as a Heterologous Booster in Adolescents

    by Ignasi Esteban Riera, Raúl Pérez-Caballero, Silvina Natalini Martínez, Miriam González Amores, Laura Roig Soria, Laia Bernad, Santiago Cavero, Benjamin Trinité, Elena Aurrecoechea Pumar, Roc Pomarol Moyà, et al.

    Objectives: Although rare, severe complications may follow SARS-CoV-2 infection in pediatric populations. PHH-1V, a protein-based, bivalent, adjuvanted COVID-19 vaccine, demonstrated strong immunogenicity and favorable safety as a booster in adults. This study further evaluated PHH-1V as a heterologous booster in pediatric adolescent population. Study design: HIPRA-HH-3 was a phase IIb, open-label, multicenter, non-inferiority trial assessing the immunogenicity and safety of PHH-1V in 240 healthy adolescents (≥ 12 to < 18 years) previously vaccinated with BNT162b2. Immunogenicity (N = 88) was evaluated by measuring neutralizing antibodies against SARS-CoV-2 variants, total binding antibodies, and T-cell responses at day 14 post-booster, compared to young adults (≥ 18 to ≤ 25 years) (N = 81) from the previous HIPRA-HH-2 study, who had also received the PHH-1V booster vaccine. Safety endpoints included all adverse events through day 28. Results: Neutralizing titers against Omicron BA.1 (primary endpoint), WH1, Beta, and Delta variants and total binding antibodies were significantly higher in adolescents than in young adults (p < 0.001), demonstrating non-inferiority (margin < 1.5). T-cell responses against Omicron BA.1 and Beta variants also increased significantly (p < 0.001). Adverse events were mostly mild or moderate, primarily injection-site pain and headache. No serious adverse events were reported. Conclusions: PHH-1V is safe and immunogenic as a heterologous booster in adolescents, inducing both humoral and cellular responses with SARS-CoV-2 cross-variant immune recognition. These findings support the use of PHH-1V in adolescent vaccination strategies. Additional data on long-term protection in this population, including specific risk groups, remain needed. Clinical Trial Registration: NCT06234956 ( https://clinicaltrials.gov/study/NCT06234956 ) and 2023-504639-42-00 ( https://euclinicaltrials.eu/search-for-clinical-trials/?lang=en&EUCT=2023-504639-42-00 ).

  • Open Access

    Safety and immunogenicity of PHH-1V booster against SARS-CoV-2 variants, including omicron subvariants: Results from a phase IIb open-label extension study

    by María Jesús López, Maria Del Mar Vazquez, Melchor Alvarez-Mon, José Ramón Arribas, Eunate Arana-Arri, Patricia Muñoz, Jorge Navarro-Pérez, Rafael Ramos, José Molto, Susana Otero-Romero, et al.

    SARS-CoV-2 vaccination campaigns on current endemic situation would benefit from vaccine alternatives with easy logistics and accessibility, sustained response and cross-reactivity against emerging variants. Herein, safety and immunogenicity of PHH-1V, adjuvanted recombinant RBD-based vaccine, as fourth dose for the most prevalent SARS-CoV-2 variants in Spain in subjects ≥18 years was investigated for 6 months in HIPRA-HH-2 open-label extension study. Subjects received a fourth dose of PHH-1V after either two BNT162b2 doses plus one PHH-1V dose (cohort 1) or three BNT162b2 doses (cohort 2). As regulatory endpoint, neutralization titers were investigated for PHH-1 V as fourth dose vs BNT162b2 as third dose in subjects receiving previous BNT162b2-based regimens. PHH-1 V immunogenicity (GMT) was investigated against Beta, Delta, and Omicron BA.1, BA.4/5 and XBB.1.5 on Days 14, 98 and 182 post-immunization. Two hundred and eighty-eight subjects received PHH-1V. Neutralizing antibodies against Omicron BA.1 at Day 14 significantly increased after the PHH-1V as fourth booster vs the third BNT162b2 booster (GMT ratio 0.43 (95% CI: 0.28; 0.65; p-value < .0001)). PHH-1V fourth booster induced a significant increase in neutralizing titers vs baseline (GMFR on Day 14 [95% CI]: Beta 6.96 [5.23, 9.25]; Delta 6.27 [4.79, 8.22]; Omicron BA.1 9.21 [5.57, 15.21]; Omicron BA.4/5 11.80 [8.29, 16.80]; Omicron XBB.1.5 5.22 [3.97, 6.87]), remaining significantly higher up to 6 months. The most frequent adverse events were injection site pain and fatigue. As conclusion, PHH-1V booster induced sustained humoral and cellular immune response against Beta, Delta variants and cross reactivity against distant Omicron subvariants and could be an appropriate strategy for implementing heterologous vaccination campaigns.


  • Open Access

    Heterologous mRNA/MVA delivering trimeric-RBD as effective vaccination regimen against SARS-CoV-2: COVARNA Consortium

    by Laura Marcos-Villar, Beatriz Perdiguero, María López-Bravo, Carmen Zamora, Laura Sin, Enrique Álvarez, Carlos Óscar S. Sorzano, Pedro J. Sánchez-Cordón, José M. Casasnovas, David Astorgano, et al.

    Despite the high efficiency of current SARS-CoV-2 mRNA vaccines in reducing COVID-19 morbidity and mortality, waning immunity and the emergence of resistant variants underscore the need for novel vaccination strategies. This study explores a heterologous mRNA/Modified Vaccinia virus Ankara (MVA) prime/boost regimen employing a trimeric form of the receptor binding domain (RBD) of the SARS-CoV-2 spike (S) protein compared to a homologous MVA/MVA regimen. In C57BL/6 mice, the RBD was delivered during priming via an mRNA vector encapsulated in nanoemulsions (NE) or lipid nanoparticles (LNP), followed by a booster with a replication-deficient MVA-based recombinant virus (MVA-RBD). This heterologous mRNA/MVA regimen elicited strong anti-RBD binding and neutralizing antibodies (BAbs and NAbs) against both the ancestral SARS-CoV-2 strain and different variants of concern (VoCs). Additionally, this protocol induced robust and polyfunctional RBD-specific CD4 and CD8 T cell responses, particularly in animals primed with mLNP-RBD. In K18-hACE2 transgenic mice, the LNP-RBD/MVA combination provided complete protection from morbidity and mortality following a live SARS-CoV-2 challenge compared with the partial protection observed with mNE-RBD/MVA or MVA/MVA regimens. Although the mNE-RBD/MVA regimen only protects half of the animals, it was able to induce antibodies with Fc-mediated effector functions besides NAbs. Moreover, viral replication and viral load in the respiratory tract were markedly reduced and decreased pro-inflammatory cytokine levels were observed. These results support the efficacy of heterologous mRNA/MVA vaccine combinations over homologous MVA/MVA regimen, using alternative nanocarriers that circumvent intellectual property restrictions of current mRNA vaccine formulations.


  • Open Access

    SAFETY AND IMMUNOGENICITY OF A PHH-1V BOOSTER DOSE AFTER DIFFERENT PRIME VACCINATION SCHEMES AGAINST COVID-19: PHASE III CLINICAL TRIAL FINAL RESULTS UP TO ONE YEAR

    by Silvina Natalini Martínez, Rafael Ramos, Jorge Navarro-Perez, Maria Jesus Lopez, Maria del Mar Vazquez, Jose Molto, Patricia Munoz, Jose M Echave, Jose R Arribas, Melchor Alvarez, et al.

    In this phase III, open label, single arm, multicenter clinical study, we report safety, tolerability and immunogenicity of PHH-1V as a booster dose in subjects primary vaccinated against COVID-19 with the BNT162b2, mRNA-1273, ChAdOx1-S, or Ad26.COV2.S vaccines, with or without previous COVID-19 infection. A total of 2661 subjects were included in this study and vaccinated with the PHH-1V vaccine. Most treatment-emergent adverse events (TEAE) were solicited local and systemic reactions with grade 1 (58.70%) or grade 2 (27.58%) intensity, being the most frequently reported injection site pain (82.83%), fatigue (31.72%) and headache (31.23%). Additionally, immunogenicity was assessed at Baseline and Days 14, 91, 182 and 365 in a subset of 235 subjects primary vaccinated. On Day 14, geometric mean triter (GMT) in neutralizing antibody against SARS-CoV-2 Wuhan and Beta, Delta and Omicron BA.1 variants increased in all primary vaccination with a geometric mean fold raise (GMFR) of 6.90 (95% CI 4.96-9.58), 12.27 (95% CI 8.52-17.67), 7.24 (95% CI 5.06-10.37) and 17.51 (95% CI 12.28-24.97), respectively. Despite GMT decay after day 14, it remains in all cases significatively higher from baseline up to 1 year after PHH-1V booster administration and GMFR against Beta and Omicron BA.1 variants over 3 at 1 year after booster compared to baseline. PHH-1V booster vaccination elicited also a significant RBD/Spike-specific IFN-γ + T-cell responses on Day 14. Overall, PHH-1V vaccine was immunogenic and well-tolerated regardless of the previous primary vaccination scheme received with no reported cases of severe COVID-19 infection throughout the entire study.


  • Open Access

    Safety and immunogenicity of PHH-1V as booster vaccination through the Omicron era: results from a phase IIb open-label extension study up to 6 months

    by M.J. Lopez, M.M. Vazquez, M. Alvarez, J.R. Arribas, E. Arana-Arri, P. Muñoz, J. Navarro-Pérez, R. Ramos, J. Molto, S. Otero-Romero, et al.

    Background Phase IIb HIPRA-HH-2 study results showed that PHH-1V as first booster dose elicited a strong and sustained neutralising antibody response against various SARS-CoV-2 variants. Here, we report the safety and immunogenicity of a fourth booster dose of PHH-1V against the most prevalent Omicron SARS-CoV-2 variants in Spain. Methods The HIPRA-HH-2 open-label extension study (NCT05142553) evaluated the safety and immunogenicity of PHH-1V as a fourth booster dose in subjects aged ≥18 years and followed for 6 months. Subjects received a fourth dose of PHH-1V 6–12 months after a previous regime of either two doses of BNT162b2 plus a third dose of PHH-1V (Cohort 1) or three doses of BNT162b2 (Cohort 2). Primary regulatory endpoint evaluated the neutralisation titres (GMT) against Omicron BA.1 on Day 14 of PHH-1V used as fourth dose in Cohort 2 vs the BNT162b2 used as third dose in initial HIPRA-HH-2 study. The immunogenicity of PHH-1V as fourth dose was also investigated by GMTs against Beta, Delta, and Omicron BA.1, BA.4/5 and XBB.1.5 on Days 14, 98 and 182 post-immunisation in the overall study population and in Cohorts 1 and 2 versus baseline. Safety of the fourth dose was also assessed. Findings From September 2022, 288 subjects received PHH-1V as a fourth dose (Cohort 1 n=106; Cohort 2 n=182). A significant increase in neutralising antibodies against Omicron BA.1 subvariant at Day 14 was observed from the third homologous booster with mRNA vaccine compared to the fourth heterologous booster with PHH-1V (1739.02 vs 4049.01; GMT ratio 0.43 (95% CI: 0.28; 0.65; p-value < 0.0001). PHH-1V used as fourth booster induced a statistically significant increase in neutralising antibody titres 14 days after immunisation for all variants compared with baseline [GMFR on Day 14 (95%CI) was 6.96 (5.23, 9.25) for Beta variant; 6.27 (4.79, 8.22) for Delta variant; 9.21 (5.57, 15.21) for Omicron BA.1 variant; 11.80 (8.29, 16.80) for Omicron BA.4/5 variant and 5.22 (3.97, 6.87) for Omicron XBB.1.5 variant]. Titres remained significantly higher compared with baseline at 3 and 6 months post-vaccination. Cohort comparison revealed no significant differences at 14, 98 and 182 days post-vaccination. The most frequent adverse events were injection site pain (Cohort 1: 84.0%; Cohort 2: 77.5%) and fatigue (Cohort 1: 17.9%; Cohort 2: 29.1%). No subjects experienced severe COVID-19 infection. Interpretation The PHH-1V vaccine as a booster induced a potent and sustained neutralising antibody response against previous circulating Beta, Delta variants and Omicron BA.1, BA.4/5, and XBB.1.5 subvariants in subjects previously vaccinated with three doses regardless of previous regimen. These findings suggest that PHH-1V could be an appropriate strategy for upcoming heterologous vaccination campaigns. Funding HIPRA SCIENTIFIC, S.L.U (HIPRA), Spain. Unmet needs Immunity against SARS-CoV-2 will continue to increase in the community through widespread vaccination and infection. Despite this, at the individual level, the humoral response against new variants is diminished in both vaccinated and infected individuals. Booster strategies have demonstrated a reduction in the risk of not only COVID-19 infection but also of long COVID-19 or persistent post-COVID manifestations. Furthermore, heterologous booster strategies for vaccination regimens offer broad neutralising responses. However, available evidence regarding new platforms beyond mRNA-based vaccines is currently limited. Evidence before this study The PHH-1V vaccine elicits high and long-lasting levels of neutralising antibodies against all COVID-19 variants studied, as well as a strong cellular immunity response, when used as a heterologous booster in previously vaccinated individuals receiving mRNA and viral vector vaccines. However, safety and immunogenicity data on a fourth booster dose of PHH-1V against the most prevalent Omicron variants in Spain were not available at the time of the study period. Added value of this study The PHH-1V dimeric adjuvanted vaccine delivered as a fourth booster dose can induce a potent and significant neutralising antibody response against previous circulating Beta, Delta variants and Omicron BA.1, BA.4/5, and also against XBB.1.5 subvariants from Day 14 through Day 182 compared with baseline regardless of the primary vaccination received (two doses of BNT162b2 plus a third dose of PHH-1V (Cohort 1) or three doses of BNT162b2 (Cohort 2)) and confirm the higher response of PHH-1V when used as a heterologous fourth-dose booster. This open-label extension study also demonstrated that PHH-1V is well tolerated and safe irrespective of the prior booster vaccination received. Implications of all the available evidence These data confirm the advantages of heterologous booster vaccination with PHH-1V and the broad-spectrum response of the PHH-1V vaccine against the different emerging variants of COVID-19, suggesting that PHH-1V could be an appropriate booster for upcoming heterologous vaccination campaigns.

  • Open Access

    Assessment of Human SARS CoV-2-Specific T-Cell Responses Elicited In Vitro by New Computationally Designed mRNA Immunogens (COVARNA)

    by Ignasi Esteban, Carmen Pastor-Quiñones, Lorena Usero, Elena Aurrecoechea, Lorenzo Franceschini, Arthur Esprit, Josep Lluís Gelpí, Francisco Martínez-Jiménez, Núria López-Bigas, Karine Breckpot, et al.

    The COVID-19 pandemic has brought significant changes and advances in the field of vaccination, including the implementation and widespread use of encapsidated mRNA vaccines in general healthcare practice. Here, we present two new mRNAs expressing antigenic parts of the SARS-CoV-2 spike protein and provide data supporting their functionality. The first mRNA, called RBD-mRNA, encodes a trimeric form of the virus spike protein receptor binding domain (RBD). The other mRNA, termed T-mRNA, codes for the relevant HLA I and II spike epitopes. The two mRNAs (COVARNA mRNAs) were designed to be used for delivery to cells in combination, with the RBD-mRNA being the primary source of antigen and the T-mRNA working as an enhancer of immunogenicity by supporting CD4 and CD8 T-cell activation. This innovative approach substantially differs from other available mRNA vaccines, which are largely directed to antibody production by the entire spike protein. In this study, we first show that both mRNAs are functionally transfected into human antigen-presenting cells (APCs). We obtained peripheral blood mononuclear cell (PBMC) samples from three groups of voluntary donors differing in their immunity against SARS-CoV-2: non-infected (naïve), infected-recovered (convalescent), and vaccinated. Using an established method of co-culturing autologous human dendritic cells (hDCs) with T-cells, we detected proliferation and cytokine secretion, thus demonstrating the ability of the COVARNA mRNAs to activate T-cells in an antigen-specific way. Interestingly, important differences in the intensity of the response between the infected-recovered (convalescent) and vaccinated donors were observed, with the levels of T-cell proliferation and cytokine secretion (IFNγ, IL-2R, and IL-13) being higher in the vaccinated group. In summary, our data support the further study of these mRNAs as a combined approach for future use as a vaccine.

  • Open Access

    Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial

    by Júlia Corominas, Carme Garriga, Antoni Prenafeta, Alexandra Moros, Manuel Cañete, Antonio Barreiro, Luis González-González, Laia Madrenas, Irina Güell, Bonaventura Clotet, et al.


  • Open Access

    The Combination of an mRNA Immunogen, a TLR7 Agonist and a PD1 Blocking Agent Enhances In-Vitro HIV T-Cell Immune Responses

    by Lorena Usero, Lorna Leal, Carmen Elena Gómez, Laia Miralles, Elena Aurrecoechea, Ignasi Esteban, Berta Torres, Alexy Inciarte, Beatriz Perdiguero, Mariano Esteban, et al.

    The development of new strategies to achieve a functional cure for HIV remains a priority. We tested a novel HIV therapeutic vaccine using unmodified mRNA (TMEP-B) and mRNA modified by 1-methyl-3′-pseudouridylyl (TMEP-Bmod) expressing both a multiepitopic sequences from Gag, Pol, and Nef proteins, including different CD4 and CD8 T-cell epitopes functionally associated with HIV control in transfected monocyte-derived dendritic cells (MDDCs) obtained from HIV infected patients. In vitro assays were used to test the mRNAs alone and in combination with immunomodulator agents, such as the TLR-7 agonist Vesatolimod and the PD-1 antagonist Nivolumab to try to improve HIV-specific cellular immune responses. Combining the mRNAs with the immunomodulators enhanced HIV-specific T-cell responses, together with the secretion of IFNγ, IP10, MIP-1α, and MIP-1β, which are fundamental mediators of viral control. Our data suggest that the mRNA vaccine prototypes TMEP-B and TMEP-Bmod, when combined with Vesatolimod and/or Nivolumab, could achieve functional cure for patients with HIV.


  • Loading dendritic cells with gold nanoparticles (GNPs) bearing HIV-peptides and mannosides enhance HIV-specific T cell responses

    by Núria Climent, Isabel García, Marco Marradi, Fabrizio Chiodo, Laia Miralles, María José Maleno, José María Gatell, Felipe García, Soledad Penadés, Montserrat Plana